Executive summary: The author argues that fragmented and under-resourced drug regulation in Africa causes multi-year delays in access to essential medicines, and while regional coordination like the African Medicines Agency could reduce this, its success is uncertain and depends on political will, trust, and incentives.
Key points:
The author argues that regulatory delays in Africa—often 4–7 years after high-income approvals—have led to worse health outcomes, as seen with tenofovir and bedaquiline reaching patients years late despite clear benefits.
These delays are driven by submission barriers (firms must file separately in 55 countries with low financial incentive) and review barriers (limited regulatory capacity leading to multi-year approval timelines).
Cross-border “family style” regulation—harmonisation, collaborative review, reliance, and supranational models—can reduce duplication, but each has trade-offs, especially around trust and dependence on timely lead regulators.
The East African Community pilot showed that harmonisation and shared review can cut timelines (to ~240 days) and improve standards and capacity, but did not fully solve issues like selective market entry, slow national approvals, or lack of trust in joint decisions.
The African Medicines Agency (AMA) aims to scale this model continent-wide to improve coordination and health sovereignty, but remains a voluntary harmonisation body without binding authority, limiting its leverage.
The author argues the AMA’s impact will depend on whether it creates enough value for manufacturers and member states—given funding uncertainty, uneven participation (notably missing major markets), and risks of becoming an additional bureaucratic layer.
This comment was auto-generated by the EA Forum Team. Feel free to point out issues with this summary by replying to the comment, andcontact us if you have feedback.
Executive summary: The author argues that fragmented and under-resourced drug regulation in Africa causes multi-year delays in access to essential medicines, and while regional coordination like the African Medicines Agency could reduce this, its success is uncertain and depends on political will, trust, and incentives.
Key points:
The author argues that regulatory delays in Africa—often 4–7 years after high-income approvals—have led to worse health outcomes, as seen with tenofovir and bedaquiline reaching patients years late despite clear benefits.
These delays are driven by submission barriers (firms must file separately in 55 countries with low financial incentive) and review barriers (limited regulatory capacity leading to multi-year approval timelines).
Cross-border “family style” regulation—harmonisation, collaborative review, reliance, and supranational models—can reduce duplication, but each has trade-offs, especially around trust and dependence on timely lead regulators.
The East African Community pilot showed that harmonisation and shared review can cut timelines (to ~240 days) and improve standards and capacity, but did not fully solve issues like selective market entry, slow national approvals, or lack of trust in joint decisions.
The African Medicines Agency (AMA) aims to scale this model continent-wide to improve coordination and health sovereignty, but remains a voluntary harmonisation body without binding authority, limiting its leverage.
The author argues the AMA’s impact will depend on whether it creates enough value for manufacturers and member states—given funding uncertainty, uneven participation (notably missing major markets), and risks of becoming an additional bureaucratic layer.
This comment was auto-generated by the EA Forum Team. Feel free to point out issues with this summary by replying to the comment, and contact us if you have feedback.